Independence Arrives For Bausch + Lomb Through IPO Priced Lower Than Forecast
Bausch + Lomb’s Independence Launched With IPO Priced Lower Than Forecast
Executive Summary
Bausch Health shopped Bausch + Lomb IPO at share price between $21 and $24. In trading of nearly 14.4m shares on New York exchange, Bausch + Lomb’s share price stayed above opening $18.50 and reached $20.07 before closing at $20, up 11.11%.
You may also be interested in...
Bausch + Lomb Separates From Bausch Health After Delivering Its Only First-Quarter Sales Growth
Bausch Health closed Bausch + Lomb IPO offering 10% of shares instead of 20% planned. Bausch + Lomb’s $889m Q1 revenue up 1% while other Bausch Health divisions slumped.
In Flip Of Bausch Health’s Planned Order For IPOs, Bausch + Lomb Registration Comes Before Solta
“We are positioned to move forward with either the Bausch + Lomb or Solta IPO quickly when market conditions are right for each of them,” CEO Joseph Papa says at J.P. Morgan conference, but the firm’s “next step” in the process of separating the two businesses was filing with the SEC an IPO registration for Bausch + Lomb.
Bausch + Lomb IPO Will Open Tap Further For Paying Down Bausch Health Debt
Paying down Bausch Health’s debt, incurred during previous management’s expansion-by-acquisition strategy when the firm operated as Valeant, has been a box to check from the start of preparing to separate Bausch + Lomb, says CEO Joseph Papa.